Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid TumorsGlobeNewsWire • 12/07/22
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/15/22
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer InstituteGlobeNewsWire • 10/19/22
Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer MeetingGlobeNewsWire • 09/14/22
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory BoardGlobeNewsWire • 08/18/22
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/16/22
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo ModelGlobeNewsWire • 08/01/22
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302GlobeNewsWire • 07/06/22
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical TrialsGlobeNewsWire • 06/07/22
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynexGlobeNewsWire • 06/02/22
Qualigen Therapeutics' Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual MeetingGlobeNewsWire • 05/26/22
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/20/22
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/13/22
Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed IsraelGlobeNewsWire • 05/10/22
Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynexGlobeNewsWire • 05/03/22
Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice PresidentGlobeNewsWire • 04/29/22
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?InvestorPlace • 04/12/22
Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic CancersBenzinga • 04/12/22
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research ConferenceGlobeNewsWire • 04/12/22
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®GlobeNewsWire • 04/05/22